Peyronie's disease and erectile dysfunction often occur together, but they are not the same condition. Peyronie's disease is an acquired disorder in which fibrous scar tissue develops within the tunica albuginea, the strong tissue surrounding the erectile chambers. The plaque can produce curvature, narrowing, shortening, pain, or an unstable hinge during erection. Erectile dysfunction (ED) means being unable to achieve or maintain an erection sufficient for satisfactory sexual activity. Each problem can worsen the other, so an accurate assessment needs to consider penile structure, blood flow, erection quality, and psychological strain rather than treating curvature or rigidity in isolation.
What Peyronie's Disease Does to Penile Tissue
The most widely accepted model begins with injury to the tunica albuginea, sometimes from a memorable sexual event but often from repeated minor trauma that a man never notices. Normal wound healing becomes dysregulated. Inflammatory signaling, oxidative stress, and transforming growth factor beta promote fibroblast activity and excess collagen deposition. Instead of flexible tissue, a localized inelastic plaque forms.
During an erection, healthy tunical tissue expands evenly. A plaque does not stretch normally, so the penis may bend toward the affected side. Some plaques create an indentation or an hourglass shape; others cause shortening or a hinge that makes penetration difficult even when curvature appears modest. A plaque may be palpable while flaccid, although the deformity is usually clearest during erection.
Peyronie's disease is commonly described in two phases. The active phase is characterized by changing curvature or deformity, often with pain. It may last for months. In the stable phase, pain frequently improves and the shape stops changing, but the plaque and deformity can remain. This distinction matters because treatment goals and the timing of procedural or surgical options depend on whether the condition is still evolving.
Estimates of prevalence vary substantially because men may not seek care and studies use different definitions. A 2025 clinical consensus statement reported estimates from 0.4% to 20.3%, with Peyronie's disease most often recognized in men in their 50s and 60s. The same statement noted that ED is present in approximately 8% to 52% of cases.[1] The wide ranges should not be interpreted as diagnostic uncertainty; they mainly reflect different populations and methods.
Peyronie's Disease and Erectile Dysfunction: Why They Overlap
Peyronie's disease can impair erections through several pathways. First, structural deformity may prevent comfortable or mechanically stable penetration even when rigidity is otherwise adequate. A severe curve, narrowing, or hinge can therefore resemble ED in practice.
Second, plaque-related changes can interfere with the veno-occlusive mechanism that normally traps blood inside the penis. If the tunica does not compress the draining veins effectively, the erection may soften too quickly. Some men also have arterial insufficiency, meaning inadequate blood inflow. Penile Doppler ultrasound can help distinguish these patterns when the result would change management.
Third, Peyronie's disease and vascular ED share risk factors. Diabetes, hypertension, abnormal lipids, smoking, and increasing age can impair endothelial function and tissue repair. Dupuytren's contracture, a fibrotic disorder of the hand, is also associated with Peyronie's disease. These connections make a broader medical review important rather than assuming every erection problem is caused only by the plaque.
Finally, the emotional effect can be substantial. Concern about pain, visible change, partner reaction, or loss of an erection can create anticipatory anxiety. Anxiety increases sympathetic nervous system activity, which works against the smooth-muscle relaxation required for erection. This does not make the symptoms "psychological"; it means a structural condition can initiate a self-reinforcing physical and emotional cycle.
How Clinicians Diagnose Both Conditions
Diagnosis begins with a focused history. A clinician will ask when the change began, whether it is progressing, whether erections are painful, and whether penetration is possible. The direction and approximate degree of curvature, loss of length, indentation, and instability all matter. Erection hardness should be evaluated separately from shape. Validated tools such as the International Index of Erectile Function and Peyronie's Disease Questionnaire can help quantify symptoms and treatment impact.
A physical examination looks for plaque location and size, penile length, and other findings such as Dupuytren's contracture. The 2025 consensus statement concludes that history and examination are often sufficient for diagnosis.[1] Photographs taken at home during a natural erection, from standardized angles and without identifying features, may help document deformity. A clinician may instead produce an erection with an intracavernosal medication when precise measurement is needed.
Ultrasound is not mandatory for every patient. Conventional ultrasound can locate or characterize plaque, while Doppler assessment after a medically induced erection can evaluate arterial inflow and venous trapping. It is most useful when erection quality is unclear, vascular disease is suspected, or a procedure is being planned.
New penile pain, a new lump, or a changing curve warrants clinical evaluation. Sudden swelling, bruising, a popping sound, and immediate loss of erection after trauma may indicate penile fracture, which is an emergency rather than Peyronie's disease. Men should also seek prompt review if ED develops abruptly or accompanies chest symptoms, because ED may sometimes reveal broader vascular disease.
What the Evidence Says About Nonsurgical Treatment
Treatment should match the phase of disease, degree of bother, anatomy, and baseline erectile function. Observation with follow-up can be reasonable when deformity is mild, intercourse remains possible, and the man is not significantly distressed. Pain in the active phase often improves over time; a clinician may recommend a nonsteroidal anti-inflammatory drug when medically appropriate.
Penile traction therapy applies controlled mechanical force with a medical device. Some trials report modest improvements in curvature and preservation or recovery of length, but protocols and devices differ. Consistent use is important, and treatment should be supervised to reduce the risk of injury. Traction is not an instant correction and should not be improvised with unregulated devices.
Intralesional therapy delivers medication directly into the plaque. Collagenase Clostridium histolyticum is FDA-approved for eligible adult men with a palpable plaque and curvature greater than 30 degrees at the start of therapy. It is given as part of a structured injection and modeling protocol. Bruising, swelling, and pain are common; corporal rupture is uncommon but serious. Other injected agents have been studied, but evidence and regulatory status differ.
The limitations of the evidence deserve emphasis. A 2023 Cochrane review of 14 randomized trials involving 1,810 men found little high-certainty evidence for most nonsurgical approaches. Injectional collagenase appeared to offer some benefit, but the clinical importance varied and adverse events increased.[2] A 2024 network meta-analysis of 24 studies and 1,643 participants found no statistically significant advantage over placebo for curvature, plaque size, or erectile-function scores in its Bayesian analysis, despite signals for some interventions under a different statistical model.[3] These findings argue for realistic expectations and shared decision-making, not for abandoning treatment.
Oral supplements promoted for plaque reduction—including vitamin E and various antioxidant combinations—have not shown consistent, high-quality evidence that they straighten the penis. They can also interact with medications or create a false sense that a progressing condition is being treated. Extracorporeal shockwave therapy may reduce pain in some men, but evidence does not establish reliable correction of curvature. Marketing claims should therefore be weighed against guideline-supported outcomes.
Treating Erectile Dysfunction When Peyronie's Disease Is Present
Treatment for the ED component depends on its cause. Lifestyle measures that support vascular health—regular aerobic activity, resistance exercise, smoking cessation, adequate sleep, blood-pressure control, and diabetes management—may support erectile function, although they do not remove a Peyronie's plaque.
Phosphodiesterase type 5 (PDE5) inhibitors such as tadalafil, sildenafil, and vardenafil improve the nitric oxide–cyclic GMP pathway and may improve rigidity when sexual stimulation is present. They treat erectile physiology, not the established curvature itself. Limited research has explored daily PDE5 inhibition during active Peyronie's disease, but it is not a substitute for a urologic assessment or a proven plaque-directed treatment. PDE5 inhibitors require medical screening and must not be combined with nitrates; caution is also needed with certain alpha-blockers, cardiovascular conditions, and interacting drugs.
Vacuum erection devices and intracavernosal injections may support rigidity in selected men. Their role should be individualized because technique, deformity, and plaque location affect safety and comfort. When significant stable deformity prevents intercourse, surgery may be the most predictable option. Plication shortens the longer side, grafting lengthens the plaque side after incision, and penile prosthesis surgery can address medication-refractory ED while allowing additional straightening maneuvers when required. Surgery is generally considered after the deformity has stabilized, with the specific approach determined by curvature complexity, penile length, and erection quality.
Psychosexual counseling can be useful alongside medical care. It may reduce avoidance, improve communication, and address performance anxiety, but it does not imply that the structural disease is imagined. The best outcomes often come from defining the separate goals clearly: reducing pain, improving usable straightness, restoring reliable rigidity, and reducing distress.
Conclusion
Peyronie's disease is a fibrotic structural disorder, while erectile dysfunction is a functional diagnosis with vascular, neurologic, hormonal, medication-related, and psychological contributors. In men who have both, successful care requires identifying which problem is limiting sexual activity and whether the disease is active or stable. Examination is often diagnostic, ultrasound is selectively useful, and treatment may combine observation, traction, injections, ED therapy, counseling, or surgery. Because evidence for many heavily advertised remedies remains weak, early evaluation by a qualified clinician is more useful than self-treatment.
If you're exploring clinically-formulated options for the erectile-function component, OnyxMD offers physician-supervised treatment plans, including EPIQ CHEWS, starting with a free online assessment at questionnaire.getonyxmd.com. You can also browse the men's health library for additional evidence-based guidance.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Kim DS, Yang HJ, Jeong HC, Moon KH, Lee DS, Song SH, Lee WK, et al. Diagnosis and Management of Peyronie's Disease: A Clinical Consensus Statement and Recommendations from the Korean Society for Sexual Medicine and Andrology. World Journal of Men's Health. 2025;43(1):50-59. doi:10.5534/wjmh.240200
Rosenberg JE, Ergun O, Hwang EC, Risk MC, Jung JH, Edwards ME, Blair Y, Dahm P. Non-surgical therapies for Peyronie's disease. Cochrane Database of Systematic Reviews. 2023;7(7):CD012206. doi:10.1002/14651858.CD012206.pub2
Lee HY, Pyun JH, Shim SR, Kim JH. Medical Treatment for Peyronie's Disease: Systematic Review and Network Bayesian Meta-Analysis. World Journal of Men's Health. 2024;42(1):133-147. doi:10.5534/wjmh.230016
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.